Koss Olinger Consulting LLC raised its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 201.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,756 shares of the biopharmaceutical company's stock after acquiring an additional 21,225 shares during the period. Koss Olinger Consulting LLC's holdings in Royalty Pharma were worth $989,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in Royalty Pharma by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 18,539 shares of the biopharmaceutical company's stock worth $473,000 after acquiring an additional 733 shares during the period. National Bank of Canada FI raised its holdings in Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 371 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Royalty Pharma by 29.1% in the fourth quarter. Wells Fargo & Company MN now owns 70,120 shares of the biopharmaceutical company's stock worth $1,789,000 after purchasing an additional 15,790 shares in the last quarter. Invesco Ltd. raised its holdings in Royalty Pharma by 33.2% in the fourth quarter. Invesco Ltd. now owns 957,893 shares of the biopharmaceutical company's stock worth $24,436,000 after purchasing an additional 238,508 shares in the last quarter. Finally, APG Asset Management N.V. raised its holdings in Royalty Pharma by 4.8% in the fourth quarter. APG Asset Management N.V. now owns 382,906 shares of the biopharmaceutical company's stock worth $9,433,000 after purchasing an additional 17,406 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.
Royalty Pharma Stock Performance
Shares of NASDAQ RPRX traded down $1.39 during midday trading on Monday, reaching $36.19. 3,529,939 shares of the stock were exchanged, compared to its average volume of 2,686,445. The firm has a market cap of $20.35 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 2.45 and a beta of 0.55. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $38.00. The firm has a 50-day simple moving average of $35.75 and a two-hundred day simple moving average of $33.64. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.04. The firm had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. As a group, analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.
Royalty Pharma Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 15th. Royalty Pharma's payout ratio is currently 50.87%.
Analyst Ratings Changes
A number of brokerages have commented on RPRX. Wall Street Zen upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Saturday. Morgan Stanley boosted their target price on shares of Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, Citigroup boosted their target price on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, July 22nd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus target price of $49.00.
View Our Latest Research Report on RPRX
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles

Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.